2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of 2seventy bio, Inc. (NASDAQ:TSVT) have been assigned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $7.20.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a report on Wednesday.

Institutional Investors Weigh In On 2seventy bio

Institutional investors have recently modified their holdings of the stock. BBR Partners LLC grew its position in shares of 2seventy bio by 620.0% during the 3rd quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after buying an additional 155,000 shares during the last quarter. Geode Capital Management LLC grew its position in shares of 2seventy bio by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 1,176,244 shares of the company’s stock valued at $5,553,000 after buying an additional 13,144 shares during the last quarter. GSA Capital Partners LLP bought a new stake in shares of 2seventy bio during the 3rd quarter valued at about $64,000. FMR LLC grew its position in shares of 2seventy bio by 22.0% during the 3rd quarter. FMR LLC now owns 148,545 shares of the company’s stock valued at $701,000 after buying an additional 26,738 shares during the last quarter. Finally, State Street Corp grew its position in shares of 2seventy bio by 1.5% during the 3rd quarter. State Street Corp now owns 1,058,773 shares of the company’s stock valued at $4,997,000 after buying an additional 15,638 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

2seventy bio Trading Up 7.5 %

Shares of 2seventy bio stock opened at $2.57 on Thursday. 2seventy bio has a twelve month low of $2.29 and a twelve month high of $6.40. The stock has a market cap of $132.59 million, a price-to-earnings ratio of -1.38 and a beta of 1.74. The company has a fifty day moving average price of $2.72 and a 200 day moving average price of $3.85.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.